Stephane de Botton
Stephane de Botton
MCU-PH _ Gustave Roussy
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
F Wang, J Travins, B DeLaBarre, V Penard-Lacronique, S Schalm, ...
Science 340 (6132), 622-626, 2013
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
EM Stein, CD DiNardo, DA Pollyea, AT Fathi, GJ Roboz, JK Altman, ...
Blood 130 (6), 722-731, 2017
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)
C Preudhomme, C Sagot, N Boissel, JM Cayuela, I Tigaud, S de Botton, ...
Blood, The Journal of the American Society of Hematology 100 (8), 2717-2723, 2002
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
CD DiNardo, EM Stein, S de Botton, GJ Roboz, JK Altman, AS Mims, ...
New England Journal of Medicine 378 (25), 2386-2398, 2018
Incidence, Clinical Features, and Outcome of AllTrans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia
S De Botton, H Dombret, M Sanz, JS Miguel, D Caillot, R Zittoun, ...
Blood, The Journal of the American Society of Hematology 92 (8), 2712-2718, 1998
Platelet formation is the consequence of caspase activation within megakaryocytes
S de Botton, S Sabri, E Daugas, Y Zermati, JE Guidotti, O Hermine, ...
Blood 100 (4), 1310-1317, 2002
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)
N Boissel, H Leroy, B Brethon, N Philippe, S De Botton, A Auvrignon, ...
Leukemia 20 (6), 965-970, 2006
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
R Itzykson, S Thépot, B Quesnel, F Dreyfus, O Beyne-Rauzy, P Turlure, ...
Blood 117 (2), 403-411, 2011
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience
L Ades, A Guerci, E Raffoux, M Sanz, P Chevallier, S Lapusan, C Recher, ...
Blood, The Journal of the American Society of Hematology 115 (9), 1690-1696, 2010
Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype
N Boissel, A Renneville, V Biggio, N Philippe, X Thomas, JM Cayuela, ...
Blood 106 (10), 3618-3620, 2005
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes
F Damm, O Kosmider, V Gelsi-Boyer, A Renneville, N Carbuccia, ...
Blood, The Journal of the American Society of Hematology 119 (14), 3211-3218, 2012
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia
O Kosmider, V Gelsi-Boyer, M Ciudad, C Racoeur, V Jooste, N Vey, ...
Haematologica 94 (12), 1676, 2009
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results
L Ades, MA Sanz, S Chevret, P Montesinos, P Chevallier, E Raffoux, ...
Blood 111 (3), 1078-1084, 2008
High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group
AL Taksin, O Legrand, E Raffoux, T De Revel, X Thomas, N Contentin, ...
Leukemia 21 (1), 66-71, 2007
Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial)
D Caillot, A Thiébaut, R Herbrecht, S de Botton, A Pigneux, F Bernard, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2007
Ecto‐calreticulin in immunogenic chemotherapy
M Obeid, A Tesniere, T Panaretakis, R Tufi, N Joza, P Van Endert, ...
Immunological reviews 220 (1), 22-34, 2007
Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group
L Adès, S Chevret, E Raffoux, S de Botton, A Guerci, A Pigneux, ...
Journal of clinical oncology 24 (36), 5703-5710, 2006
Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter …
C Gardin, P Turlure, T Fagot, X Thomas, C Terre, N Contentin, E Raffoux, ...
Blood 109 (12), 5129-5135, 2007
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
MD Amatangelo, L Quek, A Shih, EM Stein, M Roshal, MD David, ...
Blood 130 (6), 732-741, 2017
AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations
K Yen, J Travins, F Wang, MD David, E Artin, K Straley, A Padyana, ...
Cancer discovery 7 (5), 478-493, 2017
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20